Cell Insight . Development of SARS-CoV-2 entry antivirals

[tetano]

Cell Insight


. 2024 Jan 30;3(1):100144.
doi: 10.1016/j.cellin.2023.100144. eCollection 2024 Feb. Development of SARS-CoV-2 entry antivirals

Meiyue Dong ¹ , Jazmin M Galvan Achi ² , Ruikun Du ^{1 3} , Lijun Rong ² , Qinghua Cui ^{1 3}



Affiliations

• PMID: 38323318
• PMCID: PMC10844678
• DOI: 10.1016/j.cellin.2023.100144

Free PMC article Abstract

The global outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatened human health and public safety. The development of anti-SARS-CoV-2 therapies have been essential to curb the spread of SARS-CoV-2. Particularly, antivirals targeting viral entry have become an attractive target for the development of anti-SARS-CoV-2 therapies. In this review, we elucidate the mechanism of SARS-CoV-2 viral entry and summarize the development of antiviral inhibitors targeting viral entry. Moreover, we speculate upon future directions toward more potent inhibitors of SARS-CoV-2 entry. This study is expected to provide novel insights for the efficient discovery of promising candidate drugs against the entry of SARS-CoV-2, and contribute to the development of broad-spectrum anti-coronavirus drugs.

Keywords: Antiviral inhibitors; Cell entry; SARS-CoV-2; SARS-CoV-2 variants.